Literature DB >> 29292987

Discovery of 2-Piperidinyl Phenyl Benzamides and Trisubstituted Pyrimidines as Positive Allosteric Modulators of the Prostaglandin Receptor EP2.

Jianxiong Jiang1, Tri Minh Van1, Thota Ganesh2, Raymond Dingledine2.   

Abstract

Prostaglandin E2 (PGE2) via its Gαs-coupled EP2 receptor protects cerebral cortical neurons from excitotoxic and anoxic injury, though EP2 receptor activation can also cause secondary neurotoxicity in chronic inflammation. We performed a high-throughput screen of a library of 292 000 small molecules and identified several compounds that have a 2-piperidinyl phenyl benzamide or trisubstituted pyrimidine core as positive modulators for human EP2 receptor. The most active compounds increased the potency of PGE2 on EP2 receptor 4-5-fold at 20 μM without altering efficacy, indicative of an allosteric mechanism. These compounds did not augment the activity of the other Gαs-coupled PGE2 receptor subtype EP4 and showed neuroprotection against N-methyl-d-aspartate (NMDA)-induced excitotoxicity. These newly developed compounds represent second-generation allosteric potentiators for EP2 receptor and shed light on a promising neuroprotective strategy. They should prove valuable as molecular tools to achieve a better understanding of the dichotomous action of brain EP2 receptor activation.

Entities:  

Keywords:  Allosteric potentiator; GPCR; NMDA; PGE2; TR-FRET; cAMP; cyclooxygenase; excitotoxicity; high-throughput screening; neuroinflammation; neuronal injury; neuroprotection

Mesh:

Substances:

Year:  2018        PMID: 29292987      PMCID: PMC6318807          DOI: 10.1021/acschemneuro.7b00486

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  39 in total

Review 1.  Defining the therapeutic time window for suppressing the inflammatory prostaglandin E2 signaling after status epilepticus.

Authors:  Yifeng Du; Timothy Kemper; Jiange Qiu; Jianxiong Jiang
Journal:  Expert Rev Neurother       Date:  2016-01-13       Impact factor: 4.618

2.  COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex.

Authors:  W E Kaufmann; P F Worley; J Pegg; M Bremer; P Isakson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

3.  Stimulation of prostaglandin EP2 receptors prevents NMDA-induced excitotoxicity.

Authors:  Abdullah Shafique Ahmad; Hean Zhuang; Valentina Echeverria; Sylvain Doré
Journal:  J Neurotrauma       Date:  2006-12       Impact factor: 5.269

Review 4.  Cyclooxygenase-2 in glioblastoma multiforme.

Authors:  Jiange Qiu; Zhi Shi; Jianxiong Jiang
Journal:  Drug Discov Today       Date:  2016-09-28       Impact factor: 7.851

5.  The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis.

Authors:  Xibin Liang; Qian Wang; Ju Shi; Ludmila Lokteva; Richard M Breyer; Thomas J Montine; Katrin Andreasson
Journal:  Ann Neurol       Date:  2008-09       Impact factor: 10.422

6.  The PGE2 EP2 receptor and its selective activation are beneficial against ischemic stroke.

Authors:  Muzamil Ahmad; Sofiyan Saleem; Zahoor Shah; Takayuki Maruyama; Shuh Narumiya; Sylvain Doré
Journal:  Exp Transl Stroke Med       Date:  2010-07-08

7.  Cerebroprotection by the neuronal PGE2 receptor EP2 after intracerebral hemorrhage in middle-aged mice.

Authors:  He Wu; Tao Wu; Xiaoning Han; Jieru Wan; Chao Jiang; Wenwu Chen; Hong Lu; Qingwu Yang; Jian Wang
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-08       Impact factor: 6.200

8.  Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation.

Authors:  Jianxiong Jiang; Yi Quan; Thota Ganesh; Wendy A Pouliot; F Edward Dudek; Raymond Dingledine
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-11       Impact factor: 11.205

9.  Prostaglandin E2 EP2 receptor deletion attenuates intracerebral hemorrhage-induced brain injury and improves functional recovery.

Authors:  Jenna L Leclerc; Andrew S Lampert; Matthew A Diller; Joshua B Immergluck; Sylvain Doré
Journal:  ASN Neuro       Date:  2015-04-13       Impact factor: 4.146

10.  Cyclooxygenase-2 contributes to oxidopamine-mediated neuronal inflammation and injury via the prostaglandin E2 receptor EP2 subtype.

Authors:  Xu Kang; Jiange Qiu; Qianqian Li; Katherine A Bell; Yifeng Du; Da Woon Jung; Jae Yeol Lee; Jiukuan Hao; Jianxiong Jiang
Journal:  Sci Rep       Date:  2017-08-25       Impact factor: 4.379

View more
  12 in total

1.  Small-molecule inhibition of prostaglandin E receptor 2 impairs cyclooxygenase-associated malignant glioma growth.

Authors:  Jiange Qiu; Qianqian Li; Katherine A Bell; Xue Yao; Yifeng Du; Erik Zhang; Jane J Yu; Ying Yu; Zhi Shi; Jianxiong Jiang
Journal:  Br J Pharmacol       Date:  2019-04-29       Impact factor: 8.739

2.  Suppressing pro-inflammatory prostaglandin signaling attenuates excitotoxicity-associated neuronal inflammation and injury.

Authors:  Jianxiong Jiang; Ying Yu; Erika Reime Kinjo; Yifeng Du; Hoang Phuong Nguyen; Ray Dingledine
Journal:  Neuropharmacology       Date:  2019-02-11       Impact factor: 5.250

Review 3.  G protein-coupled receptors in acquired epilepsy: Druggability and translatability.

Authors:  Ying Yu; Davis T Nguyen; Jianxiong Jiang
Journal:  Prog Neurobiol       Date:  2019-08-24       Impact factor: 11.685

4.  Inhibiting the PGE2 Receptor EP2 Mitigates Excitotoxicity and Ischemic Injury.

Authors:  Lexiao Li; Ying Yu; Ruida Hou; Jiukuan Hao; Jianxiong Jiang
Journal:  ACS Pharmacol Transl Sci       Date:  2020-06-25

5.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

6.  Inverse Agonism of Cannabinoid Receptor Type 2 Confers Anti-inflammatory and Neuroprotective Effects Following Status Epileptics.

Authors:  Ying Yu; Lexiao Li; Davis T Nguyen; Suni M Mustafa; Bob M Moore; Jianxiong Jiang
Journal:  Mol Neurobiol       Date:  2020-05-06       Impact factor: 5.590

Review 7.  PGE2 receptors in detrusor muscle: Drugging the undruggable for urgency.

Authors:  Ruida Hou; Ying Yu; Jianxiong Jiang
Journal:  Biochem Pharmacol       Date:  2020-12-09       Impact factor: 5.858

8.  Montelukast alleviates inflammation in experimental autoimmune encephalomyelitis by altering Th17 differentiation in a mouse model.

Authors:  Bing Han; Yan-Yan Zhang; Ze-Qing Ye; Yun Xiao; Javad Rasouli; Wen-Cheng Wu; Su-Min Ye; Xin-Yue Guo; Lin Zhu; Abdolmohamad Rostami; Li-Bin Wang; Yuan Zhang; Xing Li
Journal:  Immunology       Date:  2021-02-28       Impact factor: 7.215

Review 9.  Small molecules targeting cyclooxygenase/prostanoid cascade in experimental brain ischemia: Do they translate?

Authors:  Jianxiong Jiang; Ying Yu
Journal:  Med Res Rev       Date:  2020-10-22       Impact factor: 12.944

Review 10.  EP2 Antagonists (2011-2021): A Decade's Journey from Discovery to Therapeutics.

Authors:  Madison N Sluter; Ruida Hou; Lexiao Li; Nelufar Yasmen; Ying Yu; Jiawang Liu; Jianxiong Jiang
Journal:  J Med Chem       Date:  2021-08-05       Impact factor: 8.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.